Investments in Variable Interest Entities (Details Textual) (USD $)	12 Months Ended			1 Months Ended	12 Months Ended		3 Months Ended	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2011 Samsung Bio-similar Agreement [Member]	Dec. 31, 2011 Neurimmune [Member]	Dec. 31, 2009 Neurimmune [Member]	Mar. 31, 2011 Knopp [Member]	Dec. 31, 2011 Knopp [Member]	Dec. 31, 2010 Knopp [Member]	Dec. 31, 2010 Common Class B [Member] Knopp [Member]
Variable Interest Entity [Line Items]
Purchase of common shares in variable interest entities										30.00%
Investment in Variable Interest Entities (Textual) [Abstract]
Total upfront and reimbursement payment made to collaborative partner									$ 26,400,000
Remaining potential development milestone payments and royalties on commercial sales under the terms of collaboration agreement					345,000,000				265,000,000
Purchase Consideration for Variable Interest Entities									60,000,000
IPR&D charge recorded related to collaboration agreement	1,219,602,000	1,248,604,000	1,283,068,000						205,000,000
IPR&D charge allocated to noncontrolling interest									145,000,000
Payment recognized as a charge to noncontrolling interests, net of tax							10,000,000
Percentage of funding for R&D cost required in support of the collaboration agreement					100.00%
Milestone Payments Made During Period					15,000,000	7,500,000		10,000,000
Schedule of Equity Method Investments [Line Items]
Contribution from Samsung to develop, manufacture and market bio-similar pharmaceuticals				255,000,000
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage				85.00%
Proceeds from Contributions from Parent				45,000,000
Percentage of stake in entity minimum				15.00%
Percentage of stake in entity maximum				49.90%
Percentage of operations of joint venture investments on financial statements	100.00%
Percentage of net income (loss) attributable to noncontrolling interests	50.00%
Investment in biotechnology companies that are determined to be unconsolidated variable interest entities	14,600,000
Significant receivables or payables related to cost sharing arrangements with unconsolidated variable interest entities	$ 0	$ 0